LOL

The scAmavex CTAD Slides “they” don’t want you to see. (AVXL)

Last night, December 1st, Vancouverite Harvey Lalach‘s most successful stock promotion ever, Anavex (AVXL), lovingly known here as scAmavex, finally revealed long awaited, and amazingly laughable, data from their trial of blarcarmasine (aka Anavex2-73) in Alzheimer’s Disease.

As befitting a filthy reverse merger bioturd, the presentation was so laughable, the results so ludicrous, the accompanying press release so misleading that it was sure to generate intense criticism. So much so that the company quickly removed the slides from their website.

So please consider yourselves lucky, dear readers, as we have the original slide deck preserved for posterity right here.

Enjoy!

One can only wonder what Sandra and Nell think about all of this.

THE CONTENT CONTAINED IN THIS BLOG REPRESENTS ONLY THE OPINIONS OF THE AUTHOR. THE AUTHOR MAY HOLD EITHER LONG OR SHORT POSITIONS IN SECURITIES OF VARIOUS COMPANIES DISCUSSED IN THE BLOG. THIS COMMENTARY IN NO WAY CONSTITUTES INVESTMENT ADVICE, AND SHOULD NEVER BE RELIED ON IN MAKING AN INVESTMENT DECISION, EVER. THIS BLOG IS NOT A SOLICITATION OF BUSINESS: ALL INQUIRIES WILL BE IGNORED. THE CONTENT HEREIN IS INTENDED SOLELY FOR THE ENTERTAINMENT OF THE READER, AND THE AUTHOR.

Very Quick Take – The Cytoshills Make A Mistake (CYDY)

While we all anxiously await tomorrow’s CONference call from everyone’s favorite reverse-merger pink sheet Coronacrapper, Cytodyn (CYDY), the shills posting glowing comments about the company and its fearless leader The NaDDir* over at Seeking Alpha seem to have made a mistake.

On today’s ridiculous Cytodyn piece on Seeking Alpha, (here), insanely prolific Cytodyn pumper, who goes by saf1148 (bio here) made a comment at 9am, and then three minutes later replies to his or her own comment, calling out him- or herself.

CYDY-ShillTalkingToSelf

Oops! Looks like someone forgot to logout and log back in under their other screen name. Hope someone at Seeking Alpha is tracking IPs of the Cytosockpuppets.

 

*Spelled thusly, for a Double Dose of that sweet sweet stock pimpin’
THE CONTENT CONTAINED IN THIS BLOG REPRESENTS ONLY THE OPINIONS OF THE AUTHOR. THE AUTHOR MAY HOLD EITHER LONG OR SHORT POSITIONS IN SECURITIES OF VARIOUS COMPANIES DISCUSSED IN THE BLOG. THIS COMMENTARY IN NO WAY CONSTITUTES INVESTMENT ADVICE, AND SHOULD NEVER BE RELIED ON IN MAKING AN INVESTMENT DECISION, EVER. THIS BLOG IS NOT A SOLICITATION OF BUSINESS: ALL INQUIRIES WILL BE IGNORED. THE CONTENT HEREIN IS INTENDED SOLELY FOR THE ENTERTAINMENT OF THE READER, AND THE AUTHOR.

Quick Take – Bye Bye Mark Ahn (GALE)

As tweeted last night by The Street.com’s Adam Feuerstein, the smug Mark Ahn is out at dreadful Galena Biopharmaceutical (GALE). Read more here.

The sell-side analysts whoring themselves out for banking business, like Needham’s moronic Chad Messer (read about him here and here) will now have to dust off the pads and kneel before newly promoted GALE CEO Mark Schwartz.

For those playing at home, the case to watch (or better yet send in an FOIA request) is:

In the Matter of Galena Biopharma, SEC File No. HO 12356 now known as  “In the Matter of Certain Stock Promotions”

No wonder the GALE-eediots have been so silent recently.

THE CONTENT CONTAINED IN THIS BLOG REPRESENTS ONLY THE OPINIONS OF THE AUTHOR. THE AUTHOR MAY HOLD EITHER LONG OR SHORT POSITIONS IN SECURITIES OF VARIOUS COMPANIES DISCUSSED IN THE BLOG. THIS COMMENTARY IN NO WAY CONSTITUTES INVESTMENT ADVICE, AND SHOULD NEVER BE RELIED ON IN MAKING AN INVESTMENT DECISION, EVER. THIS BLOG IS NOT A SOLICITATION OF BUSINESS: ALL INQUIRIES WILL BE IGNORED. THE CONTENT HEREIN IS INTENDED SOLELY FOR THE ENTERTAINMENT OF THE READER, AND THE AUTHOR.

Galena and the Epsilon Sock Puppets – GALE

A number of comments have recently been submitted for approval to the recent posts on bio-dreck Galena Biopharma (GALE), by commenters “Don Petty” and “Bryce in TX“. [Similar comments have been posted to other articles on other site, like Seeking Alpha, by Don and Bryce as well.]

Both seem to be stubbornly stupid GALE bulls.

It turns out that all 6 comments are from the exact same email address and posted from the same ip address. Nice try.

(more…)

Quick Take – The Uri Landesman Magical Mystery Tour (ECTE, NEOP)

Our good friend, and Mark Nordlicht‘s right hand man, Uri Landesman was back on the air this holiday-shortened week, discussing everyone’s favorite tired old bio-dreck, reverse merger company Echo Therapeutics (ECTE) and bucket shop IPO Neoprobe (NEOP). Read more about ECTE here, and a great piece on NEOP, by Martin Shkreli, here. And check out Uri’s performance!

Happy Holidays!

The content contained in this blog represents only the opinions of the author. The author may hold either long or short positions in securities of various companies discussed in the blog. This commentary in no way constitutes investment advice, and should never be relied on in making an investment decision, ever. This blog is not a solicitation of business: all inquiries will be ignored. The content herein is intended solely for the entertainment of the reader, and the author.

Congratulations Echo He! (HRBN)

In a surprise victory, beating out both Carol Wang and Henry Ai, with almost 50% of the vote, the winner of the most recent Weekend Poll, “Who is the next Ping Luo?” is Maxim Group’s Echo He.

Echo released a report on Harbin Electric (HRBN), a prototypical Chinese reverse-merger company, entitled “It’s not about trust, but common sense; Reiterate Buy.” News flash for Echo, it is only about trust. And simply put, there is not a single sell-side analyst that should be trusted blindly, not ones who work at Morgan Stanley or Goldman Sachs and certainly not ones that work at third-tier SPAC shops like Maxim.

Harbin is not Echo‘s only bizarre call.

(more…)

Best penny stock executive name, ever. (JCOF)

Hot on the heels of Shane Whittle’s Jammin Java (JAMN) promotion, see here and here, comes me-too coffee stock, Pink Sheet darling Javalution (JCOF). Javalution issued a press release on the 9th of May quoting founder and President Scott Pumper.

“We are delighted that our relationship with Richmont has now moved to a new level,” said Scott Pumper, Founder and President of Javalution. “Combining our expertise in the coffee industry with the strategic business and financial experience of John Rochon and his team gives us a great launching pad to broaden Javalution’s horizon. This is an important step in our growth.”

Fabulous.

The content contained in this blog represents only the opinions of the author. The author may hold either long or short positions in securities of various companies discussed in the blog. This commentary in no way constitutes investment advice, and should never be relied on in making an investment decision, ever. This blog is not a solicitation of business: all inquiries will be ignored. The content herein is intended solely for the entertainment of the reader, and the author.